
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio Inc. is positioned positively due to strong momentum and optimistic sentiment from Key Opinion Leaders (KOLs) regarding its pipeline candidate PROSERA for pulmonary arterial hypertension (PAH), which is expected to achieve significant treatment effects as reflected in the anticipated 25 to 30-meter improvement in six-minute walk distance (6MWD). Additionally, the Phase 2 TORREY trial data demonstrated consistent benefits across multiple efficacy endpoints, including reductions in pulmonary vascular resistance and pro-BNP levels, along with a robust safety profile and promising durability observed in the open-label extension (OLE) study. The heightened interest from investors following the recent Cantor conference underscores the growing confidence in Gossamer Bio's therapeutic innovations and the potential for market success.
Bears say
Gossamer Bio Inc. faces a negative outlook due to the market's continued mispricing of seralutinib's odds, indicating potential overvaluation in light of its clinical risks. This suggests that investor sentiment may not accurately reflect the challenges and uncertainties surrounding the product's development and commercial prospects. Furthermore, the recent stock run-up may not be justified, potentially leaving investors exposed to future volatility as the company's pipeline products progress through trials.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares